Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03658642
Other study ID # HIC 2000023783
Secondary ID UG3DA047003
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2019
Est. completion date September 15, 2021

Study information

Verified date June 2022
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Emergency Departments (EDs) frequently care for individuals with Opioid Use Disorder (OUD). Buprenorphine (BUP) is an effective treatment option for patients with OUD that can safely be initiated in the ED. At present, BUP is rarely initiated as a part of routine ED care. Clinical decision support (CDS) represents a potential approach to accelerate adoption of this best practice into routine emergency care. The goal of this trial is to determine whether implementation of a user-centered clinical decision support (CDS) system can increase adoption of initiation of BUP into the routine emergency care of individuals with OUD.


Description:

The study design is an 18-month pragmatic, parallel, cluster randomized, superiority trial using constrained randomization of clusters to arms. The unit of randomization (i.e. cluster) is the ED. EDs will be randomly allocated with an allocation ratio of 1:1. Adequate lead time will be allotted to install the intervention in the electronic health records (EHR) at all intervention sites--including a three month implementation and washout phase. The intervention will then begin at the same time across all sites with the CDS intervention fully implemented in the intervention sites' EHRs at the start of the trial. Clinicians at control sites will retain all control of their practice and practice as usual without the CDS intervention installed in their EHR. Pragmatic trials study an intervention under the usual conditions in which it will be applied; as opposed to an explanatory trial which would test an intervention under ideal conditions. In cluster randomized trials, treatment intervention is allocated to clusters (i.e. groups of individuals) rather than individuals. This is done to manipulate the physical or social environment of the intervention when an individual intervention would likely result in contamination between intervention and control participants at the group level. The parallel cluster randomized design was chosen over a stepped wedge design due to the high likelihood of confounding by temporal trends from ongoing efforts to mitigate the opioid epidemic. A major challenge of the cluster randomized design is from potential confounding due to a limited number of heterogeneous groups. Constrained randomization offers a solution to this source of confounding by balancing key cluster-level prognostic factors across the study to avoid distorting estimates of treatment effect due to the confounding factors. This allocation technique more evenly distributes potential confounders between intervention arms by specifying the confounding factors, characterizing each cluster in terms of these factors, identifying a subset of randomization combinations of clusters that adequately balance confounding factors between intervention arms and randomly selecting one of these combinations as the allocation scheme. Potential confounders that will be used for this trial are: EHR vendor, ED annual volume, ED type (e.g., academic, community, urban, rural, etc), ratio of ED clinicians who have a waiver to prescribe BUP, current rate of ED BUP prescribing, resources in ED to facilitate management of patients with OUD, and willingness of staff to adopt the practice of ED-initiation of BUP. Intervention: The intervention for this study includes the user-centered CDS as well as education of ED clinicians practicing at all study sites. The need for flexibility in the graphical user interface of the intervention resulted in the decision to develop the CDS as a web application. This provides the ability to access the tool both embedded within the EHR or directly over the Internet. The web application was developed as a single-page application (SPA) based on React JavaScript library. The CDS is a user-initiated, Substitutable Medical Applications and Reusable Technologies (SMART) on Fast Health Interoperability Resources (FHIR) application that streamlines a flow diagram of the clinical protocol for ED-initiated BUP. The intervention's graphical user interface is an intuitive, simple layout presenting four care pathways in columns based on the patient's diagnosis of OUD, the severity of withdrawal, and readiness to start treatment. There is additional, optional decision support available for guidance to: 1) evaluate OUD severity based on diagnostic and statistical manual of mental disorders (DSM)-5 criteria, 2) assess withdrawal severity using the clinical opiate withdrawal scale (COWS) score, and 3) motivate patient willingness and readiness to initiate medications for opioid use disorder (MOUD) treatment with a brief motivational interview. These materials are also available to share with other members of the care team via a web address, text messaging, or Quick Response (QR) code. The interface also includes a toggle switch for the user based on whether or not they have a waiver to prescribe BUP. Clinicians without a waiver cannot prescribe BUP but can administer a one-time dose of BUP in the ED for up to 72-hours. When integrated into the local EHR system, launching a care pathway enables the user to: place orders, refer for ongoing MOUD treatment, and update clinical notes. The educational plan will be site-specific and tailored to the usual care at that institution. It will be administered within three months of the study start date. The details of the plan will be developed in partnership with local champions who self-identify an interest in helping to implement an ED-initiated BUP protocol at their site. Specifically, the education plan will be required to include: 1) A didactic on opioid use disorder, its diagnosis, assessment of withdrawal severity, and local resources for referral for ongoing MOUD treatment, 2)Circulation and posting in each study site ED of the flow diagram of the study's clinical protocol for ED-initiated BUP. Since this protocol is considered best practice, clinicians at control sites will retain all control of their practice and be encouraged to follow this protocol even though the CDS will not be available to them. 3) Intervention sites will include strategies to increase use of the intervention by training clinicians on how to launch and use the CDS. Use of the intervention will be tracked with site-specific audit and feedback that is consistent with typical quality improvement initiatives at that site. Given the ongoing and escalating opioid epidemic and wide scope of this trial, the investigators anticipate that there may be concomitant interventions to stem OUD at study sites during the trial. The investigators plan to permit these interventions as long as they are: (1) implemented before randomization so that they can be tracked and accounted for in the constrained randomization process, and (2) they are not a health IT intervention targeted at clinicians to initiate BUP in the ED.


Recruitment information / eligibility

Status Completed
Enrollment 5047
Est. completion date September 15, 2021
Est. primary completion date May 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Clinicians - All clinicians working in Emergency Departments in the selected sites Patients - 18 years or older - Will meet an EHR-derived phenotype suggesting possible OUD will be included in the analysis - Will be discharged from the ED - Not pregnant - Not currently taking any medication for Opioid Use Disorder Exclusion Criteria: Patients - Have a medical or psychiatric condition that requires hospitalization during the ED visit - Have prior enrollment in the current study - Currently in addiction treatment - Be a prisoner or in police custody at the time of ED visit Note: The CDS will also be available for physicians to use when patients do not meet the EHR phenotype. These patients will be excluded from the primary analyses

Study Design


Intervention

Behavioral:
Clinical Decision Support (CDS)
This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)

Locations

Country Name City State
United States UCHealth Anschutz Medical Campus (AMC) Aurora Colorado
United States UAB - University Hospital ED (UED) Birmingham Alabama
United States UAB Medicine Highlands - Highlands ED, (HED) Birmingham Alabama
United States Bridgeport Hospital ED (BPT), YNHHS Bridgeport Connecticut
United States UNC Hospitals Emergency Department, UNCHS Chapel Hill North Carolina
United States UCHealth Memorial Hospital Central Colorado Springs Colorado
United States UCHealth Memorial Hospital North (MHN) Colorado Springs Colorado
United States UCHealth Poudre Valley Hospital (PVH) Fort Collins Colorado
United States UAB Freestanding Emergency Department of Gardendale (GED) Gardendale Alabama
United States Baystate Franklin Greenfield Massachusetts
United States Greenwich Hospital ED (GH), YNHHS Greenwich Connecticut
United States UCHealth Medical Center of the Rockies Loveland Colorado
United States St Raphael's Campus (SRC), YNHHS New Haven Connecticut
United States Lawrence + Memorial Hospital ED (L&M), YNHHS New London Connecticut
United States Baystate Wing Hospital ED Palmer Massachusetts
United States REX Healthcare Emergency Department, UNCHS Raleigh North Carolina
United States Emergency Care Center at Nash General Hospital, UNCHS Rocky Mount North Carolina
United States Chatham Hospital ED, UNCHS Siler City North Carolina
United States Johnston Health ED, UNCHS Smithfield North Carolina
United States Baystate Springfield Hospital ED Springfield Massachusetts
United States Baystate Mary Lane Hospital ED Ware Massachusetts
United States Baystate Noble Westfield Massachusetts

Sponsors (7)

Lead Sponsor Collaborator
Yale University Mayo Clinic, National Institute on Drug Abuse (NIDA), The Cooper Health System, University of Alabama at Birmingham, University of California, Davis, University of North Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Count of Initiating BUP in the ED With Referral for Ongoing MOUD With User-centered CDS Compared With Usual Care The primary outcome will be Buprenorphine (BUP) initiation in the Emergency Department (ED), defined as whether or not an eligible patient is administered BUP in the ED and/or prescribed BUP upon discharge from the ED. Although this is not a patient-centered outcome, it is a pragmatic and meaningful surrogate that will serve as a lead indicator of the CDS intervention's effect on engaging more OUD patients in treatment. Medications for Opioid Use Disorder (MOUD) Upon discharge (Up to 1 day)
Secondary Count of Those With Referral to Follow-up for Ongoing MOUD Treatment (Patient Level) The count of enrolled patients who receive an Medication Assisted Therapy (MAT) appointment. Medications for Opioid Use Disorder (MOUD) Upon discharge (Up to 1 day)
Secondary Rates Receiving a MAT Appointment Who go to the Appointment Data will be collected in the aggregate for the percentage of patients that attended the referral MAT appointment 18 months
Secondary Number of Clinicians Providing ED-initiated BUP Number of clinicians providing ED-initiated BUP regardless of CDS 18 months
Secondary Number of Clinicians Providing Referral of Any Ongoing MOUD Treatment Number of clinicians that refer patients with OUD regardless of CDS 18 months
Secondary Number of Clinicians Who Have Received Drug Addiction Treatment Act (DATA) of 2000 Training Number of clinicians that obtained DATA waiver 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Completed NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder N/A
Completed NCT03065049 - Transforming Recovery Through Exercise and Community N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Active, not recruiting NCT04650386 - Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients N/A
Completed NCT03715634 - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine Phase 1
Enrolling by invitation NCT04991974 - Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine Phase 2/Phase 3
Completed NCT04122755 - Single Ascending Dose Study of ALA-1000 Phase 1
Recruiting NCT05049460 - Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder N/A
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Recruiting NCT05028998 - COVID-19-Related Opioid Treatment Policy Evaluation
Completed NCT05047627 - Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder N/A
Active, not recruiting NCT04129580 - reSET-O RCT (Randomized Controlled Trial) N/A
Recruiting NCT03923374 - Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Completed NCT04464421 - SMART Effectiveness Trial N/A
Suspended NCT02687360 - Imaging the Effects of rTMS on Chronic Pain N/A
Completed NCT04056182 - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment Phase 2